• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

    159.76 -2.95 (-1.81%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 12, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,055,122
    Open 162.04
    Bid (Size) 158.11 (500)
    Ask (Size) 168.68 (100)
    Prev. Close 162.71
    Today's Range 159.44 - 162.97
    52wk Range 122.14 - 169.57
    Shares Outstanding 100,100,000
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy ↗
    Via Chartmill
    NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score ↗
    Via Chartmill

    Performance

    YTD
    +13.6%
    +13.6%
    1 Month
    +2.5%
    +2.5%
    3 Month
    +25.0%
    +25.0%
    6 Month
    +3.2%
    +3.2%
    1 Year
    +28.7%
    +28.7%

    More News

    Read More
    Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82 ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and Bull Flag Breakout Setup ↗
    Via Chartmill
    Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Momentum Breakout Setup ↗
    Via Chartmill
    Neurocrine Biosciences (NASDAQ:NBIX) Shows Affordable Growth Potential ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX): A Value Gem With Solid Fundamentals ↗
    Via Chartmill
    Neurocrine Biosciences (NASDAQ:NBIX) Screens as a Peter Lynch-Style GARP Opportunity ↗
    Via Chartmill
    News headline image
    Neurocrine (NBIX) Q1 2026 Earnings Transcript ↗
    Via The Motley Fool
    Neurocrine Biosciences (NASDAQ:NBIX) Smashes Q1 Estimates with 44% Sales Surge ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Qualifies for Affordable Growth Screen with Strong GARP Profile ↗
    Via Chartmill
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: XOMA Royalty Corporation (Nasdaq – XOMA), Organon & Co. (NYSE – OGN), RE/MAX Holdings, Inc. (NYSE – RMAX), Soleno Therapeutics, Inc. (Nasdaq – SLNO)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with a Bullish Technical Setup ↗
    Via Chartmill
    Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top Affordable Growth Stock ↗
    Via Chartmill
    Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup ↗
    Via Chartmill
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Avanos Medical, Inc. (NYSE – AVNS), Leggett & Platt, Incorporated (NYSE – LEG), Soleno Therapeutics, Inc. (Nasdaq – SLNO), Forian, Inc. (Nasdaq – FORA)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
    Via MarketMinute
    News headline image
    Neurocrine Biosciences (NBIX): A New Era in Neuroscience and Endocrinology
    Via Finterra
    Topics Earnings Economy Intellectual Property
    News headline image
    Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
    Via Finterra
    Topics Economy Intellectual Property
    Wall Street Holds Its Ground While Trump's Iran Deadline Ticks Down ↗
    Via Chartmill
    Topics Government
    News headline image
    Why Soleno Therapeutics Stock Rocketed Higher on Monday ↗
    Via The Motley Fool
    News headline image
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Soleno Therapeutics, Inc. (Nasdaq – SLNO), Affinity Bancshares, Forian, Inc. (Nasdaq – FORA), Janus Henderson Group plc (NYSE - JHG)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    News headline image
    Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
    Via MarketMinute
    Topics Intellectual Property
    News headline image
    Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗
    Via The Motley Fool
    Topics Regulatory Compliance

    Frequently Asked Questions

    Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
    Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
    What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
    Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
    The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
    What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
    The current price of Neurocrine Biosciences, Inc. - Common Stock is 159.76
    When was Neurocrine Biosciences, Inc. - Common Stock last traded?
    The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 06/12/26 04:00 PM ET
    What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
    The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 15.99B
    How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
    Neurocrine Biosciences, Inc. - Common Stock has 16B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.